EUVIMEDObjevte EUVIMED
Crossref

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia

Maral Amangurbanova, Daniel Q Huang iD, Nabil Noureddin, Kaleb Tesfai, Richelle Bettencourt, Harris Siddiqi, Scarlett J Lopez, Vanessa Cervantes, Egbert Madamba, Rohit Loomba iD

Alimentary Pharmacology & Therapeutics · 2025-02 · 61 (3) · 456-464

DOI: 10.1111/apt.18377 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-11-05. Written by Maral Amangurbanova and 9 co-authors. Institution: Division of Gastroenterology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Ferritins, Liver Cirrhosis. Cited 25 times so far (Crossref); 36 references.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Elevated levels of serum ferritin, a marker of hepatic iron overload and inflammation, may be associated with metabolic dysfunction‐associated steatotic liver disease (MASLD) and hepatic fibrosis.

Aim

To determine the prevalence of MASLD and significant hepatic fibrosis among patients with type 2 diabetes mellitus (T2DM) and hyperferritinaemia.

Methods

This is a cross‐sectional analysis of a prospective cohort of 523 adults (64% female) aged 50–80 with T2DM and without a diagnosis of haemochromatosis. MASLD and significant fibrosis were defined as magnetic resonance imaging‐proton density fat fraction (MRI‐PDFF) ≥ 5% and magnetic resonance elastography (MRE) ≥ 3.0 kPa, respectively. Hyperferritinaemia was defined as serum ferritin ≥ 200 ng/mL in females or ≥ 300 ng/mL in males. The primary objective was to determine the prevalence of MASLD and significant fibrosis in hyperferritinaemia.

Results

The mean age and body mass index were 64.1 (±8.1) years and 31.5 (±5.9) kg/m 2 , respectively. The overall prevalence of hyperferritinaemia was 20.5% ( n = 107). The prevalence of MASLD (78.5% vs. 62.1%, p = 0.001) and significant fibrosis (35.5% vs. 22.1%, p = 0.002) were higher in participants with hyperferritinaemia than those without. Hyperferritinaemia remained an independent predictor of MASLD (OR 2.01; 95% CI 1.19–3.39; p = 0.009) and significant fibrosis (OR 2.33; CI 1.43–3.77; p = 0.001), even after adjustment for age, sex, obesity and insulin use.

Conclusion

Approximately 80% of people with hyperferritinaemia and T2DM have MASLD, and more than a third have significant hepatic fibrosis. Hyperferritinaemia may be a useful biomarker for MASLD and significant fibrosis in people with T2DM.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2FerritinsLiver CirrhosisHumansMaleFemaleMiddle AgedAgedProspective StudiesCross-Sectional StudiesPrevalenceAged, 80 and overFatty LiverMagnetic Resonance ImagingIron OverloadBiomarkersElasticity Imaging Techniques

Author keywords

NAFLD/MASLDhepatologyliver

Substances

FerritinsBiomarkers

Authors and institutions

  • Division of Gastroenterology, MASLD Research Center, University of California at San Diego, La Jolla, California, USA.
  • Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.
  • Division of Epidemiology, Department of Family Medicine and Public Health, University of California at San Diego, San Diego, California, USA.

ORCID profiles: Daniel Q Huang, Rohit Loomba

Cite

APA

Amangurbanova, M., Huang, D. Q., Noureddin, N., Tesfai, K., Bettencourt, R., Siddiqi, H., Lopez, S. J., Cervantes, V., Madamba, E., & Loomba, R. (2025). A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia. Alimentary Pharmacology & Therapeutics, 61(3), 456-464. https://doi.org/10.1111/apt.18377

Vancouver

Amangurbanova M, Huang DQ, Noureddin N, Tesfai K, Bettencourt R, Siddiqi H, et al. A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia. Alimentary Pharmacology & Therapeutics. 2025;61(3):456-464. doi:10.1111/apt.18377

BibTeX
@article{Amangurbanova2025,
  author = {Amangurbanova, Maral and Huang, Daniel Q and Noureddin, Nabil and Tesfai, Kaleb and Bettencourt, Richelle and Siddiqi, Harris and Lopez, Scarlett J and Cervantes, Vanessa and Madamba, Egbert and Loomba, Rohit},
  title = {A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {3},
  pages = {456--464},
  doi = {10.1111/apt.18377}
}
Start for free →